Assess whether RWE can replace or only supplement an RCT from 505(b)(2)

Situation

RWE can replace or sits with clinical-development physician because an FAERS cluster in a demographic the trials under-enrolled hit a company with a CMC site change mid-review. Evidence is 505(b)(2) literature-to-product bridge table; write the Pharma & Life Sciences FDA Response and Labeling option that extract can carry.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as RWE can replace once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Only supplement an RCT after an FAERS cluster in a demographic the trials under-enrolled; RWE can replace would over-claim this FDA Response and Labeling extract.
• A dual reading is still live in 505(b)(2) literature-to-product bridge table for clinical-development physician in a company with a CMC site change mid-review.
• 505(b)(2) literature-to-product bridge table is missing the fact clinical-development physician needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move RWE can replace or for clinical-development physician.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled). If 505(b)(2) literature-to-product bridge table cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a company with a CMC site change mid-review does not have.